Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Nikola Besic has a total of 124 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Recurrence Rate and Survival in 260 Patients With Oncocytic Thyroid Cancer According to Response to Initial Treatment – A Single-Institution Experience

    by Nikola Besic, Barbara Gazic

    Recurrence Rate and Survival in 260 Patients With Oncocytic Thyroid Cancer According to Response to Initial Treatment – A Single-Institution Experience - Article abstract #950937

  • Open Access

    Breast cancer related lymphedema and shoulder mobility following radiotherapy

    by Tamara Jarm, Nikola Besic, Romi Cencelj Arnez, Jasna But-Hadzic, Ivica Ratosa

    Purpose: Lymphedema of the arm and reduced shoulder mobility are common complications of breast cancer treatment. We aim to establish whether the radiation dose received by the area of the axillary lateral thoracic artery vessel juncture (ALTJ) and the shoulder joint—affect the development of the mentioned side effects. Methods: In this retrospective study, 298 patients with early breast cancer treated surgically and with adjuvant radiation therapy, were included. Clinical data from the prospective database were used. Physiotherapists evaluated lymphedema and shoulder mobility at diagnosis, 6 and 12 months afterwards. The ALTJ, humeral head, and humeral head with a safety margin were delineated on a CT scan, and irradiation parameters were obtained from dose-volume histograms. Results: Multivariate analysis confirmed a correlation between higher mean (Dmean) and near-minimum (D98) radiation doses received by ALTJ and the incidence of lymphedema 12 months post-diagnosis (p = 0.016 and p = 0.002, respectively). No significant association was found between the radiation dose to the humeral head and reduced mobility. Conclusion: In our cohort of patients, irradiation of the ALTJ region is associated with the occurrence of clinically-assessed lymphedema, while irradiation of the humeral head is not linked to limited mobility of the shoulder after breast cancer treatment.


  • Open Access

    Benefits of Early Integrated and Vocational Rehabilitation in Breast Cancer on Work Ability, Sick Leave Duration, and Disability Rates

    by Nina Kovacevic, Tina Žagar, Vesna Homar, Bojan Pelhan, Marko Sremec, Tina Rozman, Nikola Besic

    Objectives: Vocational rehabilitation plays a vital role in helping breast cancer survivors overcome physical, psychological, and occupational challenges, enabling a smoother return to work and improving quality of life. The aim of this study was to evaluate the effect of vocational rehabilitation as part of early integrated rehabilitation compared to conventional rehabilitation on sick leave duration, work ability, and disability rates. Methods: The study was designed as a prospective, interventional study. We enrolled 435 breast cancer patients, 211 patients in the control group, and 224 in the intervention group. The control group received the conventional rehabilitation as offered to breast cancer patients before the pilot study on individualized, integrated rehabilitation, while patients in the intervention group were referred for additional treatments and vocational rehabilitation. Results: There were no differences between the control and the intervention group of patients in terms of patient demographics, tumor size, disease stage, or oncologic treatment. However, compared to the control group, the intervention group had 50 days shorter sick leave (p = 0.002), better work ability (p < 0.001), and a lower proportion of patients with disabilities (p < 0.001) and better work ability (p < 0.001) one year after the beginning of cancer treatment. Vocational rehabilitation was likely associated with shorter sick leave (p < 0.069). Conclusions: Integrated rehabilitation was associated with shorter sick leave, and vocational rehabilitation was likely associated with shorter sick leave. Integrated rehabilitation was associated with improved work ability and disability rate.


  • Open Access

    Impact of early integrated rehabilitation on fatigue in 600 patients with breast cancer – a prospective study

    by Masa Auprih, Tina Zagar, Nina Kovacevic, Andreja Cirila Skufca Smrdel, Nikola Besic, Vesna Homar

    Background: Fatigue after breast cancer treatment is a common burden that is challenging to treat. The aim of this study was to explore if such integrated rehabilitation program reduces the prevalence of chronic fatigue compared to simple, non-integrated rehabilitation. Patients and methods: The subjects of our prospective study were 600 female breast cancer patients (29–65 [mean 52 years] of age), who participated in the pilot study on the individualized integrated rehabilitation of breast cancer patients in 2019–2021 and were monitored for one year. The control group included 301 patients and the intervention group numbered 299 patients. The patients completed three questionnaires (EORTC QLQ-C30, -BR23 and NCCN): before cancer treatment, and then six and twelve months after the beginning of cancer treatment. The control group obtained the standard rehabilitation program, while the intervention group was part of the early, individualized multidisciplinary and integrated approach of rehabilitation. The rehabilitation coordinator referred patients for additional interventions ( e.g. , psychologist, gynecologist, pain management team, physiotherapy, clinical nutrition team, kinesiologist-guided online training, vocational rehabilitation, general practitioner). Data on the patients’ demographics, disease extent, cancer treatment and complaints reported in questionnaires were collected and analyzed. Results: There were no differences between the control and the intervention group of patients in terms of age, education, disease extent, surgical procedures, systemic cancer treatment, or radiotherapy, and also no differences in the fatigue before the beginning of treatment. However, patients from the control group had a greater level of constant fatigue than patients from the intervention group half a year (p = 0.018) and a year (p = 0.001) after the beginning of treatment. Furthermore, a greater proportion of patients from the control group experienced significant interference with their usual activities from fatigue than from the intervention group, half a year (p = 0.042) and a year (p = 0.001) after the beginning of treatment. A multivariate logistic regression showed that one year after the beginning of treatment, the only independent factor correlated to fatigue was inclusion into the intervention group (p = 0.044). Inclusion in the intervention group was beneficial—patients from the control group were 1.5 times more likely to be fatigued. Conclusions: Early individualized integrated rehabilitation is associated with a lower prevalence of chronic fatigue or fatigue interfering with usual activities in breast cancer patients in comparison to the control group of patients.


  • Open Access

    Symptoms of Anxiety and Depression Among Slovenian Breast Cancer Survivors Post-Treatment During the COVID-19 Pandemic: A Cross-Sectional Study

    by Špela Miroševič, Judith Prins, Nikola Bešić, Simona Borštnar, Andreja Cirila Škufca Smrdel, Vesna Homar, Marko Popović, Zalika Klemenc-Ketiš

    Background: Although anxiety and depression are important determinants of mental health, the literature in this area is sparse as most studies focus on the period during treatment. Mental health problems can affect cancer recovery as well as quality of life and survival. In this cross-sectional study, we investigated the prevalence of anxiety and depression in Slovenian cancer survivors after treatment and assessed the associated correlates during the COVID-19 pandemic. Methods: From September 2021 to January 2022, we collected data from 430 breast cancer survivors one to five years after receiving post-local treatment and (neo)adjuvant chemotherapy. We used the Hospital Anxiety and Depression Scale (HADS) to measure anxiety and depression levels. Multivariate linear regression was used to identify factors associated with higher levels of anxiety and depression. Results: Key findings from this study are increased levels of psychological distress and identification of relevant factors associated with those elevated levels. Approximately one-third of breast cancer survivors exhibited symptoms of elevated anxiety and depression, with one in eight meeting clinical thresholds. Multivariate linear regression revealed that age, lower quality of life, heightened fear of cancer recurrence (FCR), reduced resilience, limited social support, and unmet psychosocial and emotional needs correlated with increased anxiety symptoms. Additionally, lower quality of life, higher FCR, diminished resilience, and limited social support were associated with higher depression symptomatology. Conclusions: Our study of Slovenian breast cancer survivors one to five years post-treatment observed a significant increase in anxiety and depression symptoms, possibly exacerbated by the COVID-19 pandemic. The demographic and psychosocial factors identified in this study offer valuable insights for future research. The study emphasises the importance of recognising and addressing the psychological needs of breast cancer survivors and the need to follow them throughout their cancer journey.


  • Open Access

    Evaluation of an Early Individualized Integrated Rehabilitation Program versus Standard Rehabilitation Program for Smoking Cessation in 115 Smokers Among 467 Female Breast Cancer Patients 2019-2021 in Slovenia

    by Romi Cencelj Arnez, Nikola Besic, Zlatka Mavric, Anamarija Mozetic, Tina Zagar, Vesna Homar, Nena Kopcavar Gucek, Andreja Cirila Skufca Smrdel, Jana Knific, Simona Borstnar, et al.

    BACKGROUND Cigarette smoking affects cancer risk and cardiovascular risk. Smoking cessation is very beneficial for health. This study aimed to evaluate an early individualized integrated rehabilitation program and standard rehabilitation program for smoking cessation in breast cancer patients. MATERIAL AND METHODS This prospective study included 467 breast cancer patients (29-65 (mean 52) years of age) treated at the Institute of Oncology Ljubljana from 2019 to 2021 and were followed longer than 1 year. The control group and intervention group included 282 and 185 patients, respectively. Three questionnaires were completed by patients before and 1 year after the beginning of oncological treatment. The intervention group received interventions according to the patient's needs, while the control group underwent standard rehabilitation. The data obtained from the survey were analyzed using the chi-square test and analysis of variance. RESULTS In total, 115 patients were tobacco smokers before the beginning of cancer treatment. There were no differences between the intervention and control group in the prevalence of smoking before the treatment. Before the cancer treatment, smoking was present in the intervention group in 22% and in control group in 27% (P=0.27). One year after the beginning of cancer treatment, smoking was present in the intervention group in only 10% of cases, while it was present in control group in 20% of cases. Smoking was significantly less common in the intervention group than in the control group (P=0.004). CONCLUSIONS Smoking cessation was more common after early integrated rehabilitation than after standard rehabilitation.


  • Open Access

    Treatment and outcome of patients with Graves’ disease and metastatic differentiated thyroid cancer

    by Nikola Besic, Barbara Vidergar-Kralj

    Background: The aim of the study was to report on the experience in a single tertiary cancer center about the treatment and outcome of patients with Graves’ disease (GD) and metastatic thyroid cancer as compared with patients without GD in our country. Patients and methods: Altogether, 28 patients (8 males, 20 females; 49–85 years of age; median 74 years) were treated because of differentiated thyroid cancer and distant metastasis at the time of diagnosis during a 10-year period (from 2010 to 2019) in the Republic of Slovenia. The subject of our retrospective study were four patients (three men, one female; 64–76 years of age, median 73 years) who had Graves’ disease and metastatic thyroid cancer. Results: The mean age of patients without GD and with GD was 74 years and 71 years, respectively (p = 0.36). There was a trend for male predominance in patients with GD (p = 0.06). There was no statistical difference in size of primary tumors, pT stage or pN stage between the group of patients without GD and with GD. The median length of follow-up was 3.33 years (range 0.04–7.83) and 5-year disease-specific survival was 51%. One of four patients with GD and 14 of 24 patients without GD died of thyroid cancer. There was no statistical difference in disease-specific survival between patients’ group of without GD and with GD (p = 0.59). Conclusions: In our country Slovenia, 14% of patients with metastatic differentiated thyroid carcinoma at the time of diagnosis had Graves’ disease. There was no difference in the treatment, outcome or survival of patients with GD in comparison to those without GD.


  • Open Access

    Treatment and Outcome of Patients with Graves' Disease and Metastatic Differentiated Thyroid Cancer

    by Nikola Besic, Barbara Vidergar-Kralj

    Background There are only limited data in the literature about treatment of patients who have Graves' disease (GD) and metastatic thyroid cancer. The aim of our study was to report on our experience about the treatment and outcome of patients with Graves' disease and metastatic thyroid cancer in our country. Methods Altogether, 28 patients (eight males, 20 females; 49–85 years of age; median 74 years) were treated because of differentiated thyroid cancer and distant metastasis at the time of diagnosis during a 10-year period (from 2010 to 2019) in the Republic of Slovenia. The subject of our retrospective study were four patients (three men, one female; 64–76 years of age, median 73 years) who had Graves' disease and metastatic thyroid cancer. Papillary carcinoma, Hürthle cell carcinoma, follicular and poorly differentiated thyroid carcinoma were diagnosed in 13, six, five and four patients, respectively. Graves’ disease was present in two patients with Hürthle cell carcinoma, one with papillary and one with poorly differentiated thyroid carcinoma. Results The mean age of patients without GD and with GD was 74 years and 71 years, respectively (p = 0.36). There was a trend for male predominance in patients with GD (p = 0.06). There was no statistical difference in size of primary tumors (p = 0.36), pT stage (p = 0.52) or pN stage (p = 1.00) between the group of patients without GD and with GD. Patients received multimodal treatment (total thyroidectomy N = 18, neck dissection N = 4, preoperative chemotherapy N = 3, ablation of thyroid remnant with radioiodine N = 18, therapy with radioiodine N = 18, external beam radiotherapy of the neck region N = 7 patients, external beam radiotherapy of other localisations N = 6, targeted therapy N = 10). Three patients (1/3 with GD) received only palliative treatment. The median length of follow-up was 3.33 years (range 0.04–7.83) and 5-year disease-specific survival was 51%. One of four patients with GD and 14 of 24 patients without GD died of thyroid cancer. There was no statistical difference in disease-specific survival between patients group of without GD and with GD (p = 0.59). Conclusion In our country, 14% of patients with metastatic differentiated thyroid carcinoma at the time of diagnosis had Graves’ disease. There was no difference in the treatment, outcome or survival of patients with GD in comparison to those without GD.

  • Outcome of Patients with Locally Advanced Metastatic Medullary Thyroid Cancer and Induction Therapy with Tyrosine Kinase Inhibitors in Slovenia

    by Cvetka Grasic Kuhar, Taja Lozar, Nikola Besic, Maja Music Marolt

    Background The aim of our retrospective study was to evaluate the outcome of patients with metastatic medullary thyroid cancer (MTC) treated with tyrosine kinase inhibitors (TKIs) and/or chemotherapy with the emphasis on analysis on the cohort treated by induction TKI because of locally advanced metastatic MTC. Methods We analyzed the outcome of 30 patients (21 males, 9 females; median age 63.8 years) with metastatic MTC treated between 2000–2020. Sunitinib was used in 20 patients. Results Median progression-free survival on TKI and on chemotherapy was 10.6 (95% CI 7.1–14) months and 3.5 (95% CI 1.4–5.5) months, respectively. Median overall survival from diagnosis and from metastasis presentation was 38.2 (95% CI 4.7–71.7) months and 20.9 (95% CI 13.8–27.9) months, respectively. Eight patients (five females, three males; 58–86 years of age, median age 70 years) were treated with induction TKI because of inoperable locally advanced and metastatic MTC. The response rate to induction TKI was 50%; two patients (25%) had stable disease, and two patients (25%) had progressive disease. Conclusion Our data support a new paradigm that TKIs may be the first treatment option in selected patients with locally advanced metastatic MTC, followed by locoregional treatment with surgery and/or external beam radiotherapy. Further studies are required to consolidate the presented data.


  • Open Access

    Graves disease and metastatic hormonal-active Hürthle cell thyroid cancer

    by Nikola Besic, Barbara Vidergar-Kralj, Katja Zaletel, Cvetka Grasic-Kuhar

    Rationale: A hormone-active metastatic Hürthle cell thyroid carcinoma (HCTC) and Graves disease (GD) present a therapeutic challenge and is rarely reported. Patient concerns: We present a 64-year-old male patient, who had dyspnea and left hip pain lasting 4 months. He had clinical signs of hyperthyroidism and a tumor measuring 9 cm in diameter of the left thyroid lobe, metastatic neck lymph node and metastases in the lungs, mediastinum, and bones. Diagnosis: Laboratory findings confirmed hyperthyroidism and GD. Fine-needle aspiration biopsy and cytological investigation revealed metastases of HCTC in the skull and in the 8th right rib. A CT examination showed a thyroid tumor, metastatic neck lymph node, metastases in the lungs, mediastinum and in the 8th right rib measuring 20 × 5.6 × 4.5 cm, in the left acetabulum measuring 9 × 9 × 3 cm and parietooccipitally in the skull measuring 5 × 4 × 2 cm. Histology after total thyroidectomy and resection of the 8th right rib confirmed metastatic HCTC. Interventions: The region of the left hip had been irradiated with concomitant doxorubicin 20 mg once weekly. When hyperthyroidism was controlled with thiamazole, a total thyroidectomy was performed. Persistent T3 hyperthyroidism, most likely caused by TSH-R-stimulated T3 production in large metastasis in the 8th right rib, was eliminated by rib resection. Thereafter, the patient was treated with 3 radioactive iodine-131 (RAI) therapies (cumulative dose of 515 mCi). Unfortunately, the tumor rapidly progressed after treatment with RAI and progressed 10 months after therapy with sorafenib. Outcomes: Despite treatment, the disease rapidly progressed and patient died due to distant metastases. He survived for 28 months from diagnosis. Lessons: Simultaneous hormone-active HCTC and GD is extremely rare and prognosis is dismal. Concomitant external beam radiotherapy and doxorubicin chemotherapy, followed by RAI therapy, prevented the growth of a large metastasis in the left hip in our patient. However, a large metastasis in the 8th right rib presented an unresolved problem. Treatment with rib resection and RAI did not prevent tumor recurrence. External beam radiotherapy and sorafenib treatment failed to prevent tumor growth.